biostudies-literatureUnknown13(3)Zang YLumican (<i>LUM</i>), a small leucine-rich proteoglycan, is a component of the extracellular matrix. Abnormal <i>LUM</i> expression is potentially associated with cancer progression. In the present study, we confirmed high <i>LUM</i> mRNA expression in colorectal adenocarcinoma (COAD) through the UALCAN database. The Kaplan-Meier method, univariate, and multivariate COX analysis showed that high <i>LUM</i> expression is an independent determinant of poor prognosis in COAD. A COX regression model was constructed based on clinical information and <i>LUM</i> expression. The receiver operating characteristic (ROC) curve indicated that this model was highly accurate in monitoring COAD prognosis. The co-expression network of <i>LUM</i> was determined by LinkedOmics, which showed that <i>LUM</i> expression was closely related to immune escape and the miR200 family. Furthermore, we studied the co-expression network of <i>LUM</i> and found that <i>LUM</i> could promote tumor metastasis and invasion. The Tumor Immune Estimation Resource website showed that <i>LUM</i> was closely related to immune infiltration and correlated with regulatory T cells, tumour-associated macrophages, and dendritic cells. We found that <i>LUM</i> cultivated cancer progression by targeting the miR200 family to promote epithelial-to-mesenchymal transition. These findings suggest that <i>LUM</i> is a potential target for inhibiting immune escape and carcinogenic pathways.Aging4388-4408https://www.ebi.ac.uk/biostudies/studies/S-EPMC7906189biostudies-literatureLumican inhibits immune escape and carcinogenic pathways in colorectal adenocarcinoma.PMC7906189Wang RLu YDong KZang YLiang ZDong QfalseLumican inhibits immune escape and carcinogenic pathways in colorectal adenocarcinoma.Lumican (<i>LUM</i>), a small leucine-rich proteoglycan, is a component of the extracellular matrix. Abnormal <i>LUM</i> expression is potentially associated with cancer progression. In the present study, we confirmed high <i>LUM</i> mRNA expression in colorectal adenocarcinoma (COAD) through the UALCAN database. The Kaplan-Meier method, univariate, and multivariate COX analysis showed that high <i>LUM</i> expression is an independent determinant of poor prognosis in COAD. A COX regression model was constructed based on clinical information and <i>LUM</i> expression. The receiver operating characteristic (ROC) curve indicated that this model was highly accurate in monitoring COAD prognosis. The co-expression network of <i>LUM</i> was determined by LinkedOmics, which showed that <i>LUM</i> expression was closely related to immune escape and the miR200 family. Furthermore, we studied the co-expression network of <i>LUM</i> and found that <i>LUM</i> could promote tumor metastasis and invasion. The Tumor Immune Estimation Resource website showed that <i>LUM</i> was closely related to immune infiltration and correlated with regulatory T cells, tumour-associated macrophages, and dendritic cells. We found that <i>LUM</i> cultivated cancer progression by targeting the miR200 family to promote epithelial-to-mesenchymal transition. These findings suggest that <i>LUM</i> is a potential target for inhibiting immune escape and carcinogenic pathways.2021-01-01T00:00:00Z2021 Jan2024-11-20T09:45:03.306Z2021-03-07T08:15:20ZS-EPMC79061893349313310.18632/aging.202401